二トシル酸ラパチニブ HYDRATE 価格 もっと(2)

メーカー	製品番號(hào)	製品説明	CAS番號(hào)	包裝	価格	更新時(shí)間	購入
富士フイルム和光純薬株式會(huì)社(wako)	W01MAS090594	二トシル酸ラパチニブ hydrate Lapatinib ditosylate hydrate	388082-78-8	250mg	￥260800	2024-03-01	購入
富士フイルム和光純薬株式會(huì)社(wako)	W01MAS090594	二トシル酸ラパチニブ hydrate Lapatinib ditosylate hydrate	388082-78-8	1g	￥579600	2024-03-01	購入

二トシル酸ラパチニブ HYDRATE 化學(xué)特性,用途語,生産方法

効能

抗悪性腫瘍薬, 受容體チロシンキナーゼ阻害薬

商品名

タイケルブ (ノバルティスファーマ)

使用

Lapatinib ditosylate monohydrate is a form of Lapatinib I, an orally active drug for breast cancer as a dual EGFR and erbB-2 inhibitor.

一般的な説明

Lapatinib is available in 250-mg tablets for oral administrationand is used in combination with cabecitabine in thetreatment of breast cancer for those patients that over expressthe type 2 EGF-R and who have previously receivedtaxane, anthracycline, and trastuzumab therapy. The type 2EGF-R is one subtype of this receptor and is also known asHER2 or ErbB-2. The agent is a receptor TK inhibitor targetingthe ErbB-1 and ErbB-2 subtypes. Binding occurs atthe ATP-binding site and thereby prevents phosphorylationand the subsequent activation of other kinase enzymes.ErbB-1 overexpression occurs in approximately27% to 30% of breast cancers, while ErbB-2 is over expressedin 20% to 25% of cases.The agent has demonstratedIC50 values of ＜0.2μM against ErbB-1 and 2 fromseveral different cancer cell lines and dissociates slowly(t_1/2＝300 min) from these receptor TKs.The drug isboth a substrate and an inhibitor of the efflux transportersPgp and BCRP. It is also an inhibitor of the hepatic uptaketransporter OATP1B1, which is an organic anion transporter.The absorption of lapatinib is incomplete andvariable after oral administration. The agent is extensivelymetabolized by CYP3A4 and CYP3A5, with minor contributionsfrom CYP2C19 and CYP2C8. Lapatinib inhibitsCYP3A and CYP2C8 at clinically relevant concentrations.The agent is highly (99%) protein bound and eliminatedprimarily in the feces. The half-life of the agent increaseupon repeated dosing, taking 6 days to reach steady statethat gives an effective half-life of 24 hours. The most commonlyseen adverse effects of lapatinib therapy are skinrash and diarrhea. Skin rash is commonly seen with manyof the other TK inhibitors and agents that target ErbB-1.Lapatinib-induced diarrhea is usually mild to moderate.There have been reports of decreases in left ventricularejection fraction associated with the agent, although thisappears to occur only rarely and is reversible upon discontinuationof therapy.

二トシル酸ラパチニブ HYDRATE 上流と下流の製品情報(bào)

原材料

準(zhǔn)備製品

二トシル酸ラパチニブ HYDRATE 生産企業(yè)

名前	電話番號(hào)	電子メール	國籍	製品カタログ	優(yōu)位度
ANHUI CHICO CHEMICAL CO., LTD.	13057662806	kirsten@chicopharm.com	China	2620	58
Hebei Chuanghai Biotechnology Co., Ltd	+86-15350571055	Sibel@chuanghaibio.com	China	8738	58
Hebei Yanxi Chemical Co., Ltd.	+86-17531190177	faithe@yan-xi.com	China	5853	58
HangZhou RunYan Pharma Technology Co.,LTD.	+86-18882027439	sales2@runyanpharma.com	China	302	58
SHANDONG BOYUAN PHARMACEUTICAL CO., LTD.	+86-531-88625728 +86-15806417970	sales@boyuanpharm.com	China	181	58
Apeloa production Co.,Limited	+86-19131931000	admin@apcl.com.cn	China	861	58
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.	+86-18600796368	sales@sjar-tech.com	China	538	58
Capot Chemical Co.,Ltd.	+86-（0）57185586718 +86-13336195806	sales@capot.com	China	29640	60
Beijing Cooperate Pharmaceutical Co.,Ltd	010-60279497	sales01@cooperate-pharm.com	CHINA	1803	55
Henan Tianfu Chemical Co.,Ltd.	+86-0371-55170693 +86-19937530512	info@tianfuchem.com	China	21585	55

388082-78-8(二トシル酸ラパチニブ HYDRATE)キーワード:

---

• 388082-78-8
• benzenesulfonic acid: N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6 -[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine: h ydrate
• N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine bis(4-methylbenzenesulfonate)
• Lapatinib Ditosilate
• Lapatinib, Tykerb, GW572016
• Lapatinib Ditosylate (GW-572016)
• lapatinib(GW572016)
• bis(N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(Methylsulfonyl)ethylaMino)Methyl)furan-2-yl)quinazolin-4-aMine) tetrakis(4-Methylbenzenesulfonate) hydrate
• Lapatinb
• 4-QuinazolinaMine, N-[3-chloro-4-[(3-fluorophenyl)Methoxy]phenyl]-6-[5-[[[2-(Methylsulfonyl)ethyl]aMino]Methyl]-2-furanyl]-, bis(4-Methylbenzenesulfonate), Monohydrate (9CI)
• N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine bis(4-methylbenzenesulfonate) monohydrate
• 4-QuinazolinaMine, N-[3-chloro-4-[(3-fluorophenyl)Methoxy]phenyl]-6-[5-[[[2-(Methylsulfonyl)ethyl]aMino]Methyl]-2-furanyl]-, bis(4-Methylbenzenesulfonate), Monohydrate
• xyene sulfonate lapatinib
• (N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(Methylsulfonyl)ethylaMino)Methyl)furan-2-yl)quinazolin-4-aMine)bis(4-Methylbenzenesulfonate) hydrate
• Lapatinib ditosylate N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine bis(4-methylbenzenesulfonate)
• N-(3-Chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)-quinazolin-4-ylamine ditosylate hydrate
• Rapatinib bis - toluene sulfonate
• GW-572016;GW572016
• Lapatinib xylene sulfonate
• N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine, 4-methylbenzenesulfonate, hydrate (1:2:1)
• Lapatinib Ditosylate MonohydrateI
• Lapatinib ditosylate hydrat
• Lapatinib ditoluenesulfonate monohydrate
• Lapatinib tosilate hydrate
• Lapatinib ditosylate ISO 9001：2015 REACH
• Lapatinib D4 DitosylateQ: What is Lapatinib D4 Ditosylate Q: What is the CAS Number of Lapatinib D4 Ditosylate
• Lapatinib tosilate
• Lapatinib ditosylate Monohydrate
• Lapatinib ditosylate hydrate
• Lapatinib p-toluenesulfonate monohydrate
• GW2016 ditosylate
• 二トシル酸ラパチニブ HYDRATE
• 二トシル酸ラパチニブ MONOHYDRATE
• ラパチニブトシル酸塩水和物
• ラパチニブトシル酸塩水和物 (JAN)
• ラパチンB
• (-)-ラバチンB
• (1S,4S,13S)-1,2-ジヒドロスピロ[1,4-エタノ-6H-ピラジノ[2,1-b]キナゾリン-13,3′(2′H)-[1H]インドール]-2′,3,6(4H)-トリオン
• (4S)-1α,4α-[[(S)-2-オキソインドリン-3,3-ジイル]メチレン]-1,3,4,6-テトラヒドロ-2H-ピラジノ[2,1-b]キナゾリン-3,6-ジオン
• (1'S,3S,12'S)-1,2-ジヒドロ-2',10',16'-トリアザスピロ[インドール-3,13'-テトラシクロ[10.2.2.02,11.04,9]ヘキサデカン]-4',6',8',10'-テトラエン-2,3',15'-トリオン
• (13S)-1,2-ジヒドロスピロ[1α,4α-エタノ-6H-ピラジノ[2,1-b]キナゾリン-13,3′(2′H)-[1H]インドール]-2′,3,6(4H)-トリオン